Erythrocyte antioxidant glutathione and malondialdehyde levels in erythrocytes and plasma glutathione S-transferase levels were estimated in patients with colorectal cancer and compared to controls. Further, the patients underwent four weeks of radiotherapy with adjuvant chemotherapy. The same parameters were estimated after four weeks of radiotherapy and compared.with pretreatment levels. It was observed that there was a decrease in erythrocyte glutathione and malondialdehyde levels in patients with colorectal cancer compared to controls, but not in case of GST. However, after chemoradiotherapy, there were no statistically significant differences in all the parameters studied.
INTRODUCTION
Colorectal cancers ranks third in frequency in men and second in women. The incidence is higher in developed countries than in developing countries (1). Alteration in the oxidant-antioxidant profile is known to occur in cancer (2, 3) . Oxidative stress due to damage brought about by free radicals is also known to influence the response of these patients to therapy. Moreover the body's defence mechanisms would play a role in the form of antioxidants and try to minimize the damage, adapting itself to the above stressful situation.
In the present study, the following parameters were assessed in the erythrocytes and plasma to elucidate the oxidant-antioxidant status in patients with colorectal cancer. Erythrocyte glutathione (GSH) levels were estimated as an index of antioxidant status. Malondialdehyde (MDA) levels were measured as thiobarbituric acid reacting substances (TBARS) which served as an index of extent of lipid peroxidation. These parameters were estimated in RBC's to try to assess the 
MATERIALS AND METHODS
The study was conducted in patients with histologically proven colorectal carcinoma. Patients selected were in Duke's stage B of colorectal cancer. Twenty healthy individuals of matching age and sex were used as controls.
The controls and patients were divided into three groups: blood samples obtained from these subjects were used for the estimation of GSH and MDA in erythrocytes and GST in plasma. GSH was estimated by the method of Beutler et al using dithio his nitro benzoic acid (DTNB) (4), MDA was determined as the measure of TBARS (5) and GST was measured by using 1-chloro-2,4 dinitrobenzene (CDNB) (6) . All reagents used were of analytical reagent grade. DTNB, CDNB and thiobarbitudc acid were obtained from Sigma chemicals, St Louis, MO.
Statistical analysis between group 1 (controls) and group 2 (pretreatment) was performed by the unpaired t-test using the Statview package. Statistical analysis between group 2 (pretreatment) and group 3 (post treatment) was 'done by the unpaired t-test by using the same package.
RESULTS AND DISCUSSION
The mean + SD of erythrocyte GSH and MDA are indicated in the table 1. There was a statistically significant decrease in the GSH and MDA levels in group 2 compared to group 1. The levels of plasma GST did not show any significant change between controls and in patients before treatment. Following four weeks of radiotherapy, the GSH, MDA and GST levels showed no statistical difference compared to pretreatment levels (p 9 0.05).
In the present study, GSH, an antioxidant was significantly decreased in patients with colorectal carcinoma when compared to controls. The decrease in the GSH levels may be due to the increased turnover of GSH for preventing oxidative damage in these patients. Similar reports of lowered GSH levels in cancers have been reported eadier by Ahmed et al. (7) in patients with cervical cancer. They have observed that GSH levels were mainly reduced in poorly differentiated tumours than in well and moderately differentiated tumours. Reduced glutathione levels in cancer were also reported by Bhuvarahamurthy etal. (3) and Faber et al. (8) . GSH depletion is reported in hepatoma at an advanced stage (9) . An increase in tumour tissue glutathione levels in oral squamous cell carcinoma has been reported by Subapriya et al. (10) .
In our study lipid peroxidation product i.e, malondialdehyde (MDA) has been decreased in the erythrocytes of patients with colorectal cancer. Gerber et al. MDA is reported to be an unstable intermediate in the peroxidation sequence of unsaturated fatty acids. It may be metabolised further or be transported (13) . This may explain the observation of decrease in MDA Jin erythrocytes in our subset of patients. Skrzydlewska et al have reported increased activity of superoxide dismutase, glutathione peroxidase and glutathione reductase (enzymatic oxidant defence system) and a decrease in GSH content (non-enzymatic antioxidant parameter) in cancer tissue suggesting an increased defence against oxidant damage in cancer (14) . However MDA levels have been reported to be higher in patients with malignant breast tumor (15, *p < 0.0001 compared to controls **p = 0.05 compared to controls. ns -not significant when compared to controls (p > 0.05) NS -not significant when compared to pre treatment (p 9 0.05) 16), colorectal cancer tissue (17) and in erythrocytes of rats with hepatoma (9).
The mean + SD values of glutathione (GSH), malondlaldehyde (MDA) and glutathione S-transferase (GST) in controls & patients (Pie & Post Treatment) with colorectal cancer
We have observed no significant difference in the levels of GST in controls and patients with colorectal cancer. The GST levels in tumor tissue of colorectal cancer were similar to the GST levels in the normal colorectal tissue of subjects with colorectal cancer (17) . No significant difference in activity of GST was observed in human breast cancer tumor cell line and Adriamycin resistant cell line. This indicates that GST may not appear to play a role in drug resistance (18) . GST levels were found to be decreased in uterine cervical carcinoma (3, 19) and in fibroadenoma and adenocarcinoma of breast (16) . An increase in GST in oral tumor tissue has been reported by Saroja et al. (2, 10) .
In our study eight patients with histologically proven colorectal cancer underwent 4 weeks of radiotherapy with adjuvant chemotherapy. The levels of GSH, MDA in erythrocytes and plasma GST were estimated in these patients.
No significant difference was observed between the pretreatment and post treatment levels. This may be because of the small sample size used for the follow-up study. GSH detoxification system is one of the defense systems against free radicals and carcinogens. Lower levels of GSH may favor an overproduction of free radicals and lipid peroxides which in turn may induce damage to the cell membrane and cellular molecules (DNA, RNA) leading to neoplasia. Similarly lower erythrocyte GSH levels in cervical cancer patients was reported by Mukundan et al. (20) . They have hypothesised that there may be an impairment of the GSH scavenger system due to the carcinogenic process. Bhuvarahamurthy et at. have reported a decrease in GST and GSH levels in cervical cancer. They have reported a varying degree of normalisation of the biochemical parameters after therapy. They have observed that different types of therapy had different responses (3).
Antioxidants like vitamin E,-vitamin C, glutathione and azelastine hydrochlodde have been used in patients with head and neck tumors receiving combined radiotherapy and chemotherapy. Inclusion of azelastine had decreased the incidence of severe mucositis in the patients (21) .
High levels of GSH cause drug resistance in the tumor tissue. Buthionine Sulfoximine (BSO) causes depletion of GSH and increases the susceptibility of the tumor tissue to anticancer drugs. The clinical trials for efficacy of BSO are being carded out. Inhibitors of GST are also reported to sensitize tumour cells to alkylating agents (22) . The measurement of erythrocyte GSH levels may be used as indicators of intracellular GSH levels. Thus measurement of erythrocyte GSH levels may be used as an alternative to measure GSH levels in tumor tissues during BSO administration. This would provide an easier method to assess GSH and GST levels and their effects on therapy.
